These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 20410924)
21. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228 [TBL] [Abstract][Full Text] [Related]
22. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
23. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359 [TBL] [Abstract][Full Text] [Related]
24. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213 [TBL] [Abstract][Full Text] [Related]
28. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359 [TBL] [Abstract][Full Text] [Related]
29. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Barbui T; Falanga A Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982 [TBL] [Abstract][Full Text] [Related]
30. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927 [TBL] [Abstract][Full Text] [Related]
31. JAK and MPL mutations in myeloid malignancies. Tefferi A Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515 [TBL] [Abstract][Full Text] [Related]
32. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Kilpivaara O; Levine RL Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026 [TBL] [Abstract][Full Text] [Related]
33. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Passamonti F; Maffioli M; Caramazza D; Cazzola M Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683 [TBL] [Abstract][Full Text] [Related]
35. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia]. Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800 [TBL] [Abstract][Full Text] [Related]
36. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT. Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847 [TBL] [Abstract][Full Text] [Related]
37. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797 [TBL] [Abstract][Full Text] [Related]
38. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Kawamata N; Ogawa S; Yamamoto G; Lehmann S; Levine RL; Pikman Y; Nannya Y; Sanada M; Miller CW; Gilliland DG; Koeffler HP Exp Hematol; 2008 Nov; 36(11):1471-9. PubMed ID: 18723266 [TBL] [Abstract][Full Text] [Related]
39. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia. Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876 [TBL] [Abstract][Full Text] [Related]
40. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Tibes R; Bogenberger JM; Benson KL; Mesa RA Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]